Baker Bros. Advisors’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Baker Bros. Advisors’s Portfolio GNMX Stock Details GNMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-3,950,419	Closed	-$2.77M	–	100
2018 Q4	$2.77M	Hold	3,950,419	–	–	0.02%	66
2018 Q3	$4.86M	Sell	3,950,419 -104,723	-3%	-$117K	0.03%	71
2018 Q2	$4.5M	Hold	4,055,142	–	–	0.03%	79
2018 Q1	$8.15M	Hold	4,055,142	–	–	0.07%	65
2017 Q4	$4.87M	Sell	4,055,142 -491,284	-11%	-$671K	0.04%	79
2017 Q3	$5.73M	Buy	4,546,426 +2,928,337	+181%	+$3.74M	0.05%	73
2017 Q2	$2.15M	Hold	1,618,089	–	–	0.02%	85
2017 Q1	$3.01M	Buy	1,618,089 +737,550	+84%	+$3.34M	0.02%	79
2016 Q4	$4.56M	Hold	880,539	–	–	0.04%	67
2016 Q3	$4.91M	Hold	880,539	–	–	0.04%	71
2016 Q2	$4.89M	Buy	880,539 +115,539	+15%	+$607K	0.05%	75
2016 Q1	$3.37M	Hold	765,000	–	–	0.04%	83
2015 Q4	$4.61M	Buy	+765,000	New	+$5.19M	0.04%	81

Other funds holding GNMX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Baker Bros. Advisors's GNMX Position: Q1 2019 in Review

Baker Bros. Advisors sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2019, closing a stake of 3,950,419 shares — an estimated $2.77M sold.

Baker Bros. Advisors first reported a position in GNMX in Q4 2015 and held it in 13 quarters. The position peaked at $8.15M in Q1 2018. 28 funds tracked by Wall St. Rank hold GNMX as of Q1 2019.

Baker Bros. Advisors reported no remaining Aevi Genomic Medicine Inc position as of Q1 2019 after selling out during the quarter.
Baker Bros. Advisors sold 3,950,419 Aevi Genomic Medicine Inc shares in Q1 2019, an estimated $2.77M.
Baker Bros. Advisors first reported a position in Aevi Genomic Medicine Inc in Q4 2015 and held it in 13 quarters.
Baker Bros. Advisors's Aevi Genomic Medicine Inc position peaked at $8.15M in Q1 2018.
28 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2019.

Based on Baker Bros. Advisors's 13F filing for Q1 2019, filed 15 May 2019.